Head and Neck Cancer Archives • BioTech Health X

Head and Neck Cancer

5 posts

Head and neck cancer is the second most prevalent type of cancer in the world. It accounts for 6% – 7% of all human cancers, with about 650,000 new cases diagnosed every year. It is one of the deadliest forms of cancer.

The rate of new cases has been increasing rapidly since the beginning of this century. The highest frequency is observed in Eastern Asia and in countries of the North-Atlantic region. The disease affects men more often than women.

The most common site of head and neck cancer is the oral cavity. Throat cancer (carcinoma of the larynx) is the second most common type, followed by cancers of the nasal cavity and paranasal sinuses.

Head and neck cancers arise from different cell types in the head and neck region. The cells that give rise to head and neck cancers can come from any of the following:

– Oral cavity: cancer of the lips, tongue, cheeks, gums, floor of the mouth, or roof of the mouth

– Nasal cavity and paranasal sinuses: cancer of the nose, sinuses, or nasopharynx

– Larynx: cancer of the voice box

– Salivary glands: cancer of the parotid gland, submandibular gland, or sublingual gland.

The cause of head and neck cancer is not fully understood.

CEL-SCI Multikine Phase 3 Data Highlighted at ESMO 2022

BioTech Health X

September 14, 2022

Biotech NewsCEL-SCI Multikine Phase 3 Data Highlighted at ESMO 2022

8 minute read

CEL-SCI recently presented its Phase 3 data at ESMO 2022, which revealed that Neoadjuvant Multikine achieved groundbreaking tumor…

Merck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial

BioTech Health X

July 20, 2022

Biotech NewsMerck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial

3 minute read

Today Merck & Co. (NYSE: MRK) announced that Keytruda has failed the Phase 3 clinical trial KEYNOTE-412 evaluating…

EF Hutton Initiates Coverage of Cel-Sci CVM with 17 Price Target Ahead of Rumored News

BioTech Health X

April 20, 2022

Biotech NewsEF Hutton Initiates Coverage of Cel-Sci (CVM) with $17 Price Target Ahead of Rumored News

5 minute read

Tim Moore, CFA an Analyst at EF Hutton has recently published a report citing the opportunities for growth…

Exclusive Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future

Jak Thomson

September 7, 2021

BioTech CEO InterviewsExclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future

10 minute read

About Cel-Sci Corporation Cel-Sci Corporation is a publicly traded biotechnology business which develops, manufactures, and markets treatments focused…

Istari Oncology Begins Phase 1 : Phase 2 Sub-Study To Evaluate PVSRIPO in Head and Neck Cancer Patients

BioTech Health X

August 19, 2021

Biotech NewsIstari Oncology Begins Phase 1 / Phase 2 Sub-Study To Evaluate PVSRIPO in Head and Neck Cancer Patients

3 minute read

Istari Oncology, Inc., a clinical-stage biotechnology firm focused on unique immunotherapy systems for the treatment of strong lumps,…

Head and Neck Cancer

Biotech NewsCEL-SCI Multikine Phase 3 Data Highlighted at ESMO 2022

Biotech NewsMerck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial

Biotech NewsEF Hutton Initiates Coverage of Cel-Sci (CVM) with $17 Price Target Ahead of Rumored News

BioTech CEO InterviewsExclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future

Biotech NewsIstari Oncology Begins Phase 1 / Phase 2 Sub-Study To Evaluate PVSRIPO in Head and Neck Cancer Patients

Virios Therapeutics Stock Plunges 70% on Fibromyalgia Clinical Trial Failure Results

CEL-SCI Multikine Phase 3 Data Highlighted at ESMO 2022

Mayo Clinic, Hibiscus BioVentures, and Innoforce Announce Mayflower Cell and Gene Therapy Accelerator

SyneuRx CEO Dr. Emil Tsai Exclusive Interview with Insights & Projections

Krystal Biotech Announces FDA IND Acceptance for KB407 Cystic Fibrosis Clinical Trial

ImmunityBio Announces FDA Acceptance of BLA for N-803 Anktiva Bladder Cancer Drug

Brickell Biotech Regains Nasdaq Compliance Meeting Minimum Bid Price Requirement

Ocugen Announces FDA Clinical Hold Removal for Phase 2/3 COVAXIN (BBV152) Clinical Trial

Hello, I’m
BioTech Health X